France's Virbac Q3 revenue rises on strength in Both Companion Animal, Farm Animal segments

By Reuters News


Overview

  • France animal health firm's Q3 revenue grew 8.8% at constant exchange rates and scope

  • YTD September 2026 revenue rose 7.9% at constant exchange rates and scope

  • Company confirmed 2026 guidance at upper end of revenue growth range


Outlook

  • Virbac targets upper end of 2026 revenue growth range of 5.5% to 7.5% at CERS

  • Company expects 2026 adjusted recurring operating income margin of around 17% at CERS

  • Virbac does not anticipate material impact from inflation or Middle East risks on 2026 outlook


Result Drivers

  • SEGMENT GROWTH - Both Companion Animal (+8.8%) and Farm Animal (+7.0%) segments contributed to revenue growth, with Supercharge platforms (excluding Thyronorm) up about 11% at constant rates and scope

  • VOLUME AND PRICING - Strong volume/mix effect of about +6%, supplemented by price increases of about +2%

  • THYRONORM ACQUISITION - Thyronorm acquisition contributed 1.3 percentage points to overall growth year to date


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 400 mln


Reuters Recommended Reads

  • Oct 19 - Roche puts future German investments 'on hold'

  • Oct 19 - China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.